EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management

Mrinal M Patnaik iD, Ayalew Tefferi iD

American Journal of Hematology · 2024-06 · 99 (6) · 1142-1165

DOI: 10.1002/ajh.27271 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 07.03.2024. Verfasst von Mrinal M Patnaik und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Leukemia, Myelomonocytic, Chronic. Die Arbeit wurde bisher 104-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Center for Biomedical Informatics and Information Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disease Overview Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes and myeloproliferative neoplasms, characterized by prominent monocytosis and an inherent risk for leukemic transformation (~15%–20% over 3–5 years). Diagnosis Newly revised diagnostic criteria include sustained (>3 months) peripheral blood (PB) monocytosis (≥0.5 × 10 9 /L; monocytes ≥10% of leukocyte count), consistent bone marrow (BM) morphology, 95% harbor somatic mutations: TET2 (~60%), SRSF2 (~50%), ASXL1 (~40%), RAS pathway (~30%), and others. The presence of ASXL1 and DNMT3A mutations and absence of TET2 mutations negatively impact overall survival ( ASXL1 WT / TET2 MT genotype being favorable). Risk Stratification Several risk models serve similar purposes in identifying high‐risk patients that are considered for allogeneic stem cell transplant (ASCT) earlier than later. Risk factors in the Mayo Molecular Model (MMM) include presence of truncating ASXL1 mutations, absolute monocyte count >10 × 10 9 /L, hemoglobin

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelomonocytic, ChronicHumansRisk AssessmentMutationHematopoietic Stem Cell Transplantation

Autor:innen und Institutionen

  • Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Mrinal M Patnaik, Ayalew Tefferi

Förderung

  • NCI NIH HHS
  • Center for Biomedical Informatics and Information Technology

Zitieren

APA

Patnaik, M. M., & Tefferi, A. (2024). Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management. American Journal of Hematology, 99(6), 1142-1165. https://doi.org/10.1002/ajh.27271

Vancouver

Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management. American Journal of Hematology. 2024;99(6):1142-1165. doi:10.1002/ajh.27271

BibTeX
@article{Patnaik2024,
  author = {Patnaik, Mrinal M and Tefferi, Ayalew},
  title = {Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management},
  journal = {American Journal of Hematology},
  year = {2024},
  volume = {99},
  number = {6},
  pages = {1142--1165},
  doi = {10.1002/ajh.27271}
}
Kostenlos starten →